Global Azilsartan Medoxomil API Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Azilsartan Medoxomil API Market Research Report 2024
Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase.
According to Mr Accuracy reports’s new survey, global Azilsartan Medoxomil API market is projected to reach US$ 56 million in 2034, increasing from US$ 15 million in 2024, with the CAGR of 20.0% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Azilsartan Medoxomil API market research.
Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Azilsartan Medoxomil API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co
Segment by Type
0.99
Others
20 mg Tablets
40 mg Tablets
80 mg Tablets
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Azilsartan Medoxomil API report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Azilsartan Medoxomil API market is projected to reach US$ 56 million in 2034, increasing from US$ 15 million in 2024, with the CAGR of 20.0% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Azilsartan Medoxomil API market research.
Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Azilsartan Medoxomil API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co
Segment by Type
0.99
Others
Segment by Application
20 mg Tablets
40 mg Tablets
80 mg Tablets
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Azilsartan Medoxomil API report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices